Reasons why some cancer cell therapy research is transitioning from CAR-T to CAR-NK.
Despite CAR-T cell therapy’s clinical efficacy, it losses target antigen after therapy. NK cells have a spontaneous cytotoxic activity that is effective even when tumour antigen is downregulated.